Dendritic cell-based human immunodeficiency virus vaccine.
Dendritic cells (DC) have profound abilities to induce and coordinate T-cell immunity. This makes them ideal biological agents for use in immunotherapeutic strategies to augment T-cell immunity to HIV infection. Current clinical trials are administering DC-HIV antigen preparations carried out ex vivo as proof of principle that DC immunotherapy is safe and efficacious in HIV-infected patients. These trials are largely dependent on preclinical studies that will provide knowledge and guidance about the types of DC, form of HIV antigen, method of DC maturation, route of DC administration, measures of anti-HIV immune function and ultimately control of HIV replication. Additionally, promising immunotherapy approaches are being developed based on targeting of DC with HIV antigens in vivo. The objective is to define a safe and effective strategy for enhancing control of HIV infection in patients undergoing antiretroviral therapy.
Rinaldo
C R
CR
Department of Infectious Diseases, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA. rinaldo@pitt.edu
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D017951:Antigen Presentation / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
D016915:AIDS Vaccines